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Introduction
Hyperlipidemias are significant risk factors for various cardiovascular, for example, atherosclerosis, and metabolic disorders, such as metabolic syndrome, diabetes, and obesity. Reduced catabolism or increased production of lipoproteins causes hyperlipidemia. Statins enhance lipoprotein catabolism and reduce plasma cholesterol. Despite the success of statins, approximately 60% of statin-treated patients have adverse coronary events. Therefore, there is a need for new drugs that can be used alone or in combination with statins to reduce hyperlipidemias. A possible approach is to inhibit the synthesis of lipoproteins. Lipoproteins are assembled in the endoplasmic reticulum, matured in the Golgi, and secreted by cells. Their biosynthesis depends on two proteins: apolipoprotein B (apoB) and microsomal triglyceride transfer protein (MTP). ApoB is a structural protein. MTP is an essential chaperone for the assembly of apoB lipoproteins [1,2,3 ]. It transfers several lipids including triacylglycerols, phospholipids, and cholesteryl esters.
Microsomal triglyceride transfer protein defects and steatosis
Abetalipoproteinemia, a rare autosomal recessive disorder with defective MTP activity, is characterized by the absence of plasma apoB lipoproteins [4] . Fat accumulation (steatosis) in the intestine is uniformly observed in all abetalipoproteinemia patients. Hepatic steatosis has also been reported with MTP deficiency. Partin et al. [5] described an abetalipoproteinemia infant with substantial hepatomegaly and persistent elevated levels of serum aminotransferases but normal bilirubin levels. Microscopic examination revealed large fat droplets in hepatocytes. They also observed scattered focal accumulation of inflammatory cells. In addition to genetic defects, there is Purpose of review Microsomal triglyceride transfer protein (MTP), a chaperone for the biosynthesis of apolipoprotein B lipoproteins and CD1d, is a therapeutic candidate to decrease plasma lipids and to diminish inflammation. MTP inhibition increases plasma transaminases and tissue lipids, and therefore new approaches are needed to avoid them.
Recent findings
Inositol requiring enzyme1b has been identified as a novel intestine-specific regulator of MTP. A new function of MTP in cholesterol ester biosynthesis has been reported. The importance of the phospholipid transfer activity of MTP in the lipidation of apolipoprotein B and CD1d has been indicated. Diurnal variations in MTP expression and its induction by food availability have been observed. On the basis of these and other findings, we propose that upregulation of inositol requiring enzyme 1b, a combined reduction of cellular free cholesterol or triglyceride or both and MTP activity, specific inhibition of phospholipid or triglyceride transfer activities, and targeting of apolipoprotein B-MTP protein-protein interactions might be pursued to avoid some of the side effects associated with the inhibition of triglyceride transfer activity of MTP. We further speculate that short-lived MTP antagonists may be useful in controlling plasma and tissue lipids and in avoiding steatosis.
Summary
We have highlighted the importance of addressing the causal relationship between MTP inhibition and aberrant elevations in plasma liver enzymes. The proposed approaches may show that MTP targeting is a viable approach to lower plasma lipids. an association between low MTP expression due to a polymorphism in the promoter sequence and liver steatosis in type 2 diabetes patients [6] . Hepatitis C virus type 3 infected patients show reduced MTP activity and mRNA levels as well as high degree of steatosis [7] .
Several animal studies also indicate a relationship between decreased MTP expression and steatosis. Chronic alcohol feeding causes fatty liver and is associated with reduced MTP [8] . Transgenic expression of hepatitis C virus core protein inhibits MTP activity, reduces VLDL secretion, and causes steatosis [9] . We have shown that steatosis induced by carbon tetrachloride involves posttranslational degradation of MTP [10 ] . Similarly, inhibition of MTP in cells also results in triglyceride accumulation [11 ] . Therefore, significant reduction in MTP activity is usually associated with steatosis.
Complications associated with microsomal triglyceride transfer protein inhibition
The triglyceride transfer activity of MTP has been exploited to identify several potent antagonists [12] [13] [14] [15] 16 ]. These antagonists (Table 1) [14,16 ,17 , 18 ,19-21] inhibit triglyceride transfer activity in vitro, suppress lipoprotein assembly and secretion in vivo, and decrease plasma lipid levels in humans and animals. MTP is highly expressed in the intestine and liver; therefore, major side effects of MTP inhibition are obvious in these tissues (Fig. 1 ). The first side effect is related to the inhibition of chylomicron assembly by enterocytes and manifests as gastrointestinal disturbances such as steatorrhea and diarrhea. The second side effect is related to the inhibition of hepatic lipoprotein assembly and secretion. In about 10-30% of the individuals, MTP inhibitors increase plasma levels of liver enzymes mainly aspartate aminotransferase (AST) and alanine aminotransferase (ALT) [17 ,18 ] indicating for liver damage. Lower levels of MTP are expressed in several other tissues. Complications associated with its inhibition in other tissues, however, have not yet been appreciated and should be considered for long-term modalities, particularly those related to the inhibition of cardiac MTP.
As MTP primarily transfers neutral lipids in vitro, it has been assumed that toxicities associated with MTP inhibition and genetic ablation are due to the accumulation of neutral lipids. We should, however, realize that synthesis of neutral lipids (triglycerides and cholesterol esters) is beneficial in avoiding toxicities associated with excess free fatty acids and free cholesterol. The question then arises why MTP inhibition leads to increases in hepatic enzymes in the plasma. A common explanation provided is that MTP inhibition leads to higher, possibly toxic, amounts of neutral lipids in the liver. However, there are reports indicating that, at least, short-term use of MTP inhibitors does not always lead to an overt accumulation of hepatic lipids [14] . We are not aware of studies describing a clear-cut relationship between hepatic fat accumulation and the appearance of liver enzymes in the plasma. Assuming that the toxicity due to MTP inhibition is associated with hepatic fat, it can conceivably be avoided by upregulating mitochondrial and peroxisomal oxidation of fatty acids. This possibility has been speculated in the literature but has not yet been reported to be practical. Therefore, there is a need to question the fundamental paradigm that MTP inhibitors increase plasma hepatic enzymes solely by augmenting cellular concentrations of triglycerides and to find new ways to circumvent hepatosteatosis.
Microsomal triglyceride transfer protein inhibition and free cholesterol assimilation
Besides triglyceride accumulation, MTP inhibition enhances cellular free cholesterol levels. Iqbal et al.
[11 ] have studied the effects of genetic ablation and chemical inhibition of MTP on tissue lipids. As expected, these treatments enhanced cellular triglyceride. It was anticipated that cholesteryl esters would also increase with triglycerides. Unexpectedly, they found significantly reduced levels of cholesteryl esters in the liver Microsomal triglyceride transfer protein Hussain and Bakillah 573 and intestinal cells. More importantly, they observed a significant assimilation of free cholesterol in these cells. Mechanistic studies revealed that MTP plays a novel role in cholesteryl ester biosynthesis [11 ] . They reported that enrichment of microsomes with cholesteryl esters reduces cholesteryl ester biosynthesis, and MTP alleviates this inhibition by depositing them into apoB lipoproteins. Chemical inhibition and genetic deletion of MTP, therefore, increase cellular free cholesterol owing to reduction in cholesteryl ester biosynthesis.
Increases in cellular free cholesterol might cause tissue damage and enhance the release of hepatic enzymes into the plasma. It is known that high cellular free cholesterol levels damage extrahepatic tissues. For example, excess amounts of cellular free cholesterol induce apoptosis, especially in the arterial wall macrophages contributing to atherogenesis [22] . Enhanced free cholesterol levels in the endoplasmic reticulum of macrophages induce unfolded protein response and apoptosis [22] . On the contrary, hepatic free cholesterol is not usually considered a problem as liver can either excrete it as such or after its conversion to bile acids. This assumption may not be totally true. The success of statin therapy is due to the inhibition of hepatic 3-hydroxy-3-methyl-glutaryl (HMG) CoA reductase activity present in the endoplasmic reticulum membranes. Therefore, a more plausible explanation is that free cholesterol in the endoplasmic reticulum membrane is critical, and perturbations that lead to increases in microsomal free cholesterol may cause injury. Furthermore, Mari et al. [23] have suggested that the progression of hepatosteatosis to steatohepatitis might be related to free cholesterol, not free fatty acid or triglyceride, accumulation in the liver. The relationship between free microsomal cholesterol assimilation, MTP inhibition, and increases in plasma transaminases can be evaluated by lowering cellular free cholesterol.
Avoiding free cholesterol accumulation
A feasible approach to lower cellular cholesterol might be to inhibit HMG CoA reductase. Statins inhibit HMG CoA reductase, increase hepatic LDL receptor expression, and decrease plasma cholesterol. Therefore, it is tempting to suggest that a combined inhibition of MTP and HMG CoA reductase may be useful in lowering plasma cholesterol and avoiding cellular cholesterol accumulation. Similarly, potent inhibitors of squalene synthase can be used with MTP inhibitors to achieve these goals.
Another combinatorial approach to avoid free cholesterol accumulation is to enhance its efflux. In this regard, liver X receptor (LXR) agonists appear promising. LXRs are nuclear hormone receptors that control expression of genes involved in cholesterol efflux in macrophages, hepatic bile acid synthesis, and intestinal cholesterol absorption [24] [25] [26] . LXR agonists increase expression of ABCA1 in macrophages, enhance cholesterol efflux, and decrease atherosclerosis in apoe À/À and ldlr À/À mice. They increase hepatic bile acid synthesis and reduce hepatic cholesterol levels. These agonists upregulate ABCG5 and ABCG8 in the intestine and reduce cholesterol absorption. Unfortunately, a major side effect of LXR agonist is hypertriglyceridemia [27] . MTP inhibitors reduce hypertriglyceridemia. Therefore, it is worth examining whether LXR agonist and MTP antagonists can be used in combination to prevent hypertriglyceridemia, increases in plasma transaminases, and steatosis.
Reducing cellular triglyceride content
Cellular triglyceride buildup is a key feature of MTP inhibition. Triglyceride synthesis involves fatty acid uptake, intracellular transport to microsomes by fatty acid-binding proteins, and acylation with glycerol by several monoacylglycerol and diacylglycerol acyltransferases. Inhibition of these steps will likely reduce cellular trigly-ceride levels. In this respect, repression of liver fatty acidbinding protein along with MTP inhibition has been shown to lessen steatosis [28] . Several studies have shown that flavonoids inhibit triglyceride transfer activity of MTP [29] . These compounds affect several other biological pathways and have pleiotropic effects. For example, taxifolin, a plant flavonoid, inhibits triglyceride synthesis and MTP activity without increasing cellular lipids [20] . Therefore, joint inhibition of triglyceride synthesis and MTP activity might avoid triglyceride accumulation. This is supported by observations that diacylglycerol acyltransferase (DGAT)1-deficient mice do not develop hepatic steatosis, demonstrate increased energy expenditure, and have significantly lower levels of triglycerides in lipogenic tissues [30] . Thus, DGAT inhibition with MTP antagonism offers an attractive opportunity for therapeutic interventions in obese and diabetic patients.
In theory, cellular triglyceride levels can be reduced by upregulating fatty acid oxidation. Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that enhance fatty acid oxidation by peroxisomes [31] . Potent PPARa agonists decrease hypercholesterolemia and atherosclerosis in ldlr À/À mice [32] . A combined use of MTP inhibitors and PPARa activators has been speculated before. Still, experimental evidence for their beneficial use is lacking.
Selective intestinal microsomal triglyceride transfer protein inhibition
Another possibility is to target intestinal MTP and spare hepatic MTP. For this to be successful, there is a need to understand tissue-specific regulation of MTP as well as the effect of MTP inhibition on intestinal self-renewal and malabsorption of fat-soluble vitamins. Although MTP inhibition leads to intestinal distress, a temporal separation of drug administration and food intake avoids these complications. For example, intestinal disturbances are avoided by administering these inhibitors 4 h after supper [14] . Furthermore, steatosis associated with intestinal targeting is usually not considered a chronic problem because of its inherent property to self-renew. In fact, preclinical and clinical studies of intestine-specific MTP inhibitors show good efficacy and minimal side effects (Table 1) . For example, dirlotapide is a potent and selective intestinal MTP inhibitor used in canines to decrease lipid absorption and reduce weight [19, 33] . JTT-130 has been shown to lower plasma triglycerides and LDL cholesterol in guinea pigs without increasing hepatic triglyceride levels [21] . Similar results have been reported for SLx-4090 [16 ] . Thus, an intestine-specific inhibition of MTP may be a way for future interventions.
MTP expression is highly regulated at the transcriptional level [3 , 34, 35] . Thus, knowledge about the upstream regulators that curb tissue-specific MTP expression might be useful. Recently, it has been shown that inositol requiring enzyme 1b (IRE1b) controls intestinal MTP expression and lipoprotein assembly [36 ] . IRE1b, expressed mainly in the intestine [37] , is a membraneanchored ribonuclease residing in the endoplasmic reticulum. It has been shown to regulate MTP mRNA involving posttranscriptional degradation. Genetic ablation of IRE1b leads to hyperlipidemias in mice when subjected to high-fat, high-cholesterol diets. These diets decrease IRE1b mRNA levels and increase MTP activity, protein and mRNA levels in wild type mice. Therefore, it is anticipated that upregulation of IRE1b could be a novel way to lower intestinal MTP expression. In this regard, a comprehensive understanding of IRE1b physiology might be beneficial for future pharmacologic repression of intestinal MTP.
Inhibition of the phospholipid transfer activity of microsomal triglyceride transfer protein
Besides triglycerides, MTP also transfers phospholipids. Kinetic studies indicate two phospholipid transfer sites in MTP [38] . Evolutionary studies indicate that the phospholipid transfer activity of MTP is the most ancient and sufficient activity for apoB-lipoprotein assembly [39, 40, 41 ] . It is also involved in CD1d biosynthesis [42,43 ,44] . Brozovic et al. [45] were the first to show a relationship between MTP and CD1d. Mttp gene manipulation in hepatocytes was associated with redistribution of CD1d. Moreover, mttp-deleted mice were resistant to immunopathologies associated with invariant natural killer T (NKT) cell-mediated hepatitis and colitis [45] . Dougan et al. [42, 43 ] have proposed that MTP acts upstream of saposins and functions as an endoplasmic reticulum chaperone by loading endogenous lipids onto nascent CD1d. On the contrary, Sagiv et al. [46 ] suggested its role in the lysosomal compartment. Therefore, it is possible that inhibition of the phospholipid transfer activity may reduce lipoprotein production and help avoid inflammatory response of certain immune disorders involving CD1d. Furthermore, specific inhibition of this activity may not interfere with triglyceride transfer and cholesterol ester biosynthesis. On the contrary, toxicities associated with MTP inhibition could be related to inhibition of phospholipid transfer activity because it is important for lipoprotein and CD1d biosynthesis. Thus, there is a critical need to identify specific antagonists of triglyceride and phospholipid transfer activities of MTP.
576 Therapy and clinical trials It was relatively easy to identify inhibitors of triglyceride transfer activity because MTP is the major cellular protein that exhibits robust neutral lipid transfer activity in the presence of synthetic membrane vesicles. In contrast, cells have several proteins that transfer phospholipids. Therefore, use of cellular or tissue homogenates may result in the identification of inhibitors that may or may not inhibit MTP's phospholipid transfer activity. Ideally, purified MTP should be used to identify phospholipid transfer activity inhibitors.
Reducing microsomal triglyceride transfer protein-apolipoprotein B interactions
MTP physically interacts with apoB [1,2,13, 35, [47] [48] [49] [50] [51] . Theoretically, blocking interactions between these proteins without affecting MTP lipid transfer should reduce apoB-lipoprotein biosynthesis. We screened compounds from Atherogenics, Inc. (Alpharetta, Georgia, USA), for their ability to block apoB-MTP proteinprotein interactions, identified a compound AGI-S17 that inhibits these interactions without affecting the lipid transfer activity of MTP, and showed that this molecule significantly reduces apoB secretion in liver cells [52] . Although this establishes a proof of concept, more potent inhibitors of apoB-MTP interactions are required to determine the benefits and risks of this approach as a potential new therapy to reach lipid and lipoproteinlowering goals for cardiovascular and metabolic patients. Like conventional MTP inhibitors, disruption of apoB-MTP interaction can potentially be used in combination therapy with other lipid-lowering agents to achieve acceptable therapeutic efficacy (Table 2) .
Short-acting microsomal triglyceride transfer protein inhibitors
A long-term adverse effect of MTP inhibition is hepatic lipid accumulation. Chronic inhibition of intestinal MTP causes steatorrhea and diarrhea. Furthermore, MTP shows diurnal variations, and its expression is induced by food anticipatory activity [53 ] . It has been shown that dosing MTP inhibitors away from food intake diminishes intestinal distress [14] . On the basis of these observations, we speculate that short-acting MTP inhibitors with adequate half-lives may be effective. It will be interesting to determine whether tolerable and effective short-acting MTP inhibitors in combination with other lipid-lowering agents will have a greater utility in achieving therapeutic goals of lowering plasma lipids and avoiding hepatic fat accumulation.
Conclusion
Significant new information about MTP biology and regulation has come forth recently. This includes identi-fication of a novel role of MTP in CD1d and cholesteryl ester biosynthesis, MTP regulation by IRE1b, and identification of intestine-specific antagonists. Because of the enhanced interest in MTP research from different disciplines, we anticipate resurgence in research to inhibit MTP alone or in combination with other targets. As genetic ablation and chemical inhibition of MTP are associated with steatosis, a careful evaluation of MTP inhibitors for their safety and efficacy is required (Fig. 1) . Novel approaches to inhibit MTP with simultaneous avoidance of associated side effects are needed. Such developments may be useful in the treatment of various lipidemias, such as familial hypercholesterolemia, familial combined hyperlipidemia, and metabolic disorders such as obesity and metabolic syndrome.
